Highest-materiality recent filing
SRx Health subsidiary invests >10% of investable capital in AI/space SPV
Halo, Purely for Pets invests >10% of investable capital in Astro Investment XVII, an Astro Capital affiliate SPV.
SRx Health Solutions and EMJX Update Merger Progress, Report Treasury Returns
Deployed $18M into Gen2 digital-asset treasury hedging strategy, March 2026 return of 5.69% vs S&P 500 decline of 4.98%.
SRx Health Solutions raises up to $8.0M via Series B preferred and warrants; initial close $4.528M
Securities Purchase Agreement for up to 10,000 Series B shares ($1,000 stated value) and warrants at $0.3182 exercise price.
SRx Health Solutions receives NYSE American warning letter over 7.5M share issuance without approval
NYSE American issued public warning letter on Feb 18, 2026 citing violations of Sections 301 and 713.
SRx Health redeems Series A Preferred for $21.8M, cancels ~125M common shares
Redeemed 17,418 Series A Preferred shares at ~$21.77M; all outstanding shares eliminated.
NYSE American accepts SRx Health's compliance plan; listing extended to July 14, 2026
NYSE accepted plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
SRx Health shareholders OK name change to EMJX, EMJ Crypto acquisition
Stockholders approved name change to EMJX, Inc. and ticker to EMJX, conditioned on closing of transaction.
Aggregate purchase price ~$55M payable in stock; transaction unanimously approved by SRx Health Board.
First closing of private placement: 19,035 Series A Preferred shares and 54.5M warrants for $15.23M; additional closings at investor option up to $30.46M total.
SRx Health stockholders approve 25x share increase and up to 85:1 reverse split
Authorized shares increased from 200M to 5B; additional reverse split range 15:1 to 85:1 approved.
SRx Health Solutions dismisses auditor, enters CCAA asset sales; identifies $1.8M revenue error
Dismissed CBIZ CPAs, engaged Davidson & Company as auditor for FY2025 ending Sept 30.
SRx Health cancels 18.8M shares (60% of total) via settlement; director resigns
18.8M shares forfeited and canceled, representing ~60% of total outstanding Common Stock and Exchangeable Shares.
SRx Health Solutions' Canadian subsidiary enters CCAA restructuring; DIP financing obtained
SRx Canada obtained Initial Order under CCAA from Ontario Superior Court, including a stay of proceedings.
SRx Health appoints Kent Cunningham CEO; Adesh Vora becomes Executive Chairman; CFO gets raise
Adesh Vora resigned as CEO July 8; replaced by Kent Cunningham, previously President.
SRx Health closes $7.3M convertible note financing and secures $50M equity line of credit
Closed $7.3M convertible note financing led by insiders and existing investors; notes bear 8% interest, mature July 2027.
SRx Canada revenue C$200.5M for year ended Sep 30, 2024, net loss C$59.4M vs loss C$15.1M prior year.
SRx Health Solutions appoints new CEO, President, Chairman and CFO
Davender Sohi resigned as President effective June 10, 2025; no dispute cited.
On June 10, 2025, SRx Health Solutions, Inc. (the “ Company ”) accepted the voluntary resignation of Davender Sohi as the President of the Company, effective immediately.
Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.
Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.
Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.
Max materiality 0.90 · Median 0.75 · Most common event other_material